Bobber Biotech

Bobber Bio is an early-stage biotechnology company based in Cambridge, Massachusetts, focused on developing a novel platform for tRNA-based therapeutics. Founded in 2023 by Dr. Alex Wesselhoeft and Dr. Orkan Akaka, both former leaders at Orna Therapeutics, the company leverages deep expertise in RNA engineering to address genetic diseases. Bobber Bio's platform aims to harness the unique properties of transfer RNA (tRNA) to enable the production of functional proteins in cells where genetic mutations, such as nonsense mutations, would otherwise cause disease. Currently operating in stealth mode, the company is focused on optimizing its proprietary RNA modalities and delivery systems to expand the reach of genetic medicines. The startup represents a significant new entry in the rapidly evolving field of RNA-based drug discovery, moving beyond traditional mRNA and circular RNA approaches.